

Advanced Human Imaging to Commence US Investor Presentations to Raise US\$15m for its Initial Entry to the US NASDAQ

NOT FOR DISSEMINATION, DISTRIBUTION, RELEASE, OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES.

Advanced Human Imaging Limited (ASX: AHI) (Advanced Human Imaging) is pleased to update shareholders with the commencement of the US Investor Roadshow with Maxim Group LLC ("Maxim Group") acting as sole book-running manager for the proposed offering for the AHI initial public offering to the US Nasdaq. The investor presentations which have been arranged by Maxim Group will commence Monday November 1, 2021.

AHI has received conditional approval from the Nasdaq to list its American Depositary Shares ("ADSs"), each of which will represent a yet to be determined number of ordinary shares of AHI, on the Nasdaq Capital Market under the tick symbol "AHI". Final approval of the listing is subject to the Company paying the Nasdaq listing fee and fulfilling any remaining conditions as required by Nasdaq. The Company's ordinary shares will continue to trade in Australia on the ASX under the symbol AHI.

Furthermore, AHI has submitted an updated public filing of a registration statement on Form F-1, with the U.S. Securities and Exchange Commission (the "SEC"). The filing relates to the proposed initial US public offering (the "Offering") of its ADSs. The number of securities to be sold and the price per ADS for the Offering have been outlined in the F-1, based on a price range of US\$7.00 – US\$9.00, and based on an assumed ADS to ordinary share ratio of one (1) ADS representing nine (9) ordinary shares of AHI. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. Maxim Group is acting as sole bookrunning manager for the proposed offering.

The Offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the Offering may be obtained from: Maxim Group LLC 300 Park Ave. New York, NY 10022, at (212) 895-3745 or by accessing the SEC's website, www.sec.gov.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

This ASX announcement does not constitute an offer to sell, or the solicitation of an offer to buy, securities in any jurisdiction, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or solicitation and any sale of securities will be made in accordance with the registration requirements of the US Securities Act of 1933.

*This announcement has been approved by the board of Advanced Human Imaging Limited.

For more information please visit: www.advancedhumanimaging.com

For more information contact:

Vlado Bosanac Chief Executive Officer Advanced Human Imaging Limited E:admin@advancedhumanimaging.com Steven Richards Chief Financial Officer Advanced Human Imaging Limited

E: admin@advancedhumanimaging.com

ASX Announcement Monday 1st November 2021



About Advanced Human Imaging:

AHI has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimensions using only a smartphone both privately and accurately.

Our goal is to assist our partners by empowering their consumers with this capability. This in return gives our partners the ability to assess, assist, and communicate outcomes with their consumers when navigating day to day life. Whether this is a personal journey to better health, understanding the risk associated with their physical condition, tracking the changes they are experiencing through training, dieting, or under medical regimes, or simply wanting to be correctly sized for a garment when shopping online. The AHI technology delivers this seamlessly, privately, and cost-effectively in under one minute.

Our partner benefits from our software as a service pricing solution, that reduces with scale. Integration is made easy with the AHI modular system, based on multiple (SDKs) software development kits, allowing a partner to select the functions, measurements, and displays to suit their individual needs.

AHI has developed this capability by leveraging the power of Computer Vision, Machine Learning, and patented algorithms, to process these images on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivalled in the industry. AHI simplifies the collection of measurements and removes the human error present in traditional methods.

Forward-Looking Statements:

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Advanced Human Imaging.

Investor Presentation • ASX: AHI • Nov 2021




























Disclaimer.

This presentation ("Presentation") has been prepared by **Advanced Human Imaging Pty Ltd** ("Advanced Human Imaging" or "Company").

You must read and accept the conditions in this notice before considering the information set out in or referred to in this Presentation. If you do not agree, accept or understand the terms on which this Presentation is supplied, or if you are subject to the laws of any jurisdiction in which it would be unlawful to receive this Presentation or which requires compliance with obligations that have not been complied with in respect of it, you must immediately return or destroy this Presentation and any other confidential information supplied to you by Advanced Human Imaging. By accepting this document, you acknowledge and agree to the conditions in this notice and agree that you irrevocably release Advanced Human Imaging from any claims you may have (presently or in the future) in connection with the provision or content of this Presentation.

NO OFFER

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction (and will not be lodged with the ASIC).

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares of Advanced Human Imaging and does not and will not form any part of any contract for the acquisition of shares of Advanced Human Imaging.

SUMMARY INFORMATION

This Presentation contains summary information about Advanced Human Imaging, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Advanced Human Imaging or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act. While Advanced Human Imaging has taken every effort to ensure the accuracy of the material in the presentation, neither the Company nor its advisers have verified the accuracy or completeness of the information, or any statements and opinion contained in this Presentation.

NOT INVESTMENT ADVICE

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Advanced Human Imaging and the impact that different future outcomes may have on Advanced Human Imaging.

This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. Advanced Human Imaging is not licensed to provide financial product advice in respect of Advanced Human Imaging shares.

Cooling off rights do not apply to the acquisition of Advanced Human Imaging shares.

INVESTMENT RISK

An investment in Advanced Human Imaging shares is subject to known and unknown risks, some of which are beyond the control of Advanced Human Imaging, Advanced Human Imaging does not guarantee any particular rate of return or the performance of Advanced Human Imaging nor does it guarantee any particular tax treatment. An investment in Advanced Human Imaging should be considered as Highly Speculative and High Risk due to the start up nature of the Company and its proposed business.

FINANCIAL DATA

All dollar values in this Presentation are in Australian dollars (A\$ or AUD) unless otherwise stated.

FORWARD-LOOKING STATEMENTS

This Presentation may contain forward looking statements. The Australian words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely, 'intend', 'should', 'could', 'may, 'target', 'plan' and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. You should not place undue reliance on forward- looking statements and neither Advanced Human Imaging nor any of its directors, employees, advisers or agents assume any obligation to update such information.

DISCLAIMER

None of Advanced Human Imaging's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorized, permitted or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them.

To the maximum extent permitted by law, Advanced Human Imaging and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in an investment in Advanced Human Imaging and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise.

To the maximum extent permitted by law, Advanced Human Imaging and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation.

Statements made in this Presentation are made only as the date of this Presentation. The information in this Presentation remains subject to change without notice.

Offering Summary.

Issuer	Advanced Human Imaging Limited. ("Advanced Human Imaging" or the "Company")
Proposed Exchange / Symbol	NasdaqCM / AHI
Offering Size	\$15 million (excluding 15% over-allotment option)
Offering Type	Initial Public Offering in the US
Securities Offered	American Depositary Shares (ADSs)
Price Range	\$7.00 - \$9.00 per ADS
Anticipated use of proceeds	Research and development of our current products, business development, and marketing, with the remainder of the proceeds to be used for general corporate purposes, including, without limitation, investing in or acquiring synergistic companies that are complementary to our technologies (including, without limitation, potential investment in Jana), and providing working capital.
Underwriter	Maxim Group LLC
Anticipated Pricing	Week of November 1st, 2021

Corporate Overview.

Personal Health Information System

- Developer of a patented smartphone-based human scanning technology's that enables users to check, track, and accurately assess their body dimensions and vital signs.
- B2B companion diagnostic business model supports global customers across multiple sectors with a diverse range of data-driven applications, including:
 - Mobile Health, Telehealth, and Wellness (collectively "mHealth")
 - + Life and Health Insurance
 - + Fitness
 - + Consumer and Apparel
- Global partners utilize our technology through Software Development Kits ("SDKs") that embed our capabilities into their software programs/apps.
- Current commercial network includes 16 active
 Partnerships targeting over 7m¹ users from an available audience of over 400m.

Capital Structure

All values as at 29/10/2021

Ticker	ASX:AHI
Share Price (AUD)	A\$1.12
Current Shares On Issue (undiluted)	136.92m
Undiluted Capitalization	\$153.35m
Convertible Note	\$2.21m
Enterprise Valuation	\$154.85m
Cash at Bank (at 29/10/21)	\$715K
Fully Diluted Shares	164.63m

Approx. Monthly Burn (operating activities)

Average Burn During Previous Quarter (September '21 QTR)

\$425K*

* Adjusted to include one-off items (e.g. NASDAQ IPO costs)

Shareholder Breakdown

Staff, Board, Advisors
Shareholders

Top 10
Shareholders

Shareholders

42%

48%

61%



1. As outlined on Page 12



Investment Highlights.

- + Robust commercial network: Current agreements include 16 active Partnerships targeting over 7m1 users from an available audience of over 400m.
- + Large addressable market across 4 business verticals.
- + Cutting Edge Innovative and proprietary technology in a Global and fast-growing industry.
- + B2B business model enabling rapid growth and scalability through existing and growing networks.
- + Experienced management team with a successful track record.





















Complete Scan

The future of health assessment using only a smartphone.

Metabolic Syndrome Type-2 Diabetes

Cardiovascular Disease Heart Attack

Obesity Central Obesity Stroke

W64.74

CompleteScan is not a substitute for the clinical judgment of a health care professional.

CompleteScan does not diagnose, freat, mitigate or prevent any disease, symptom, disorder or abnormal physical state.



Mobile Device Health Information System.



BodyScan

State-of-the-art image processing and digital dimensioning.



FaceScan

30-second vital signs.



HemaScan

Remote blood diagnostics and monitoring solution.



MKScan

Functional movement assessments.

Potential Acquisition 1



DermaScan

The intelligent, instant dermatological check.

Health Risks

Obesity Type 2 Diabetes

Metabolic Syndrome 1

Body Composition Total Body Fat %

Risk Indicators

Waist-Hip Waist-Height Waist

Circumference

Technologies

Chest Waist 3D Model Thiahs Hips

Accuracy, Validation 2 97.5%

AVG ACCURACY

REPEATABILITY 1. Metabolic Syndrome is available by combining a Face Scan and BodyScan data, or supplying Blood

2. Both accuracy and repeatability have been validated by Professor Timothy Ackland, Professor of Applied. Anatomy and Biomechanics, The University of Western Australia - ASX Announcement 18/10/2018.

Health Risks

Cardiovascular Disease

Heart Attack Stroke

Vital Signs

Heart Rate Blood Pressure Respiratory Rate

Health Indicators

Stress HRV Cardiac Workload

Accuracy, Validation 1

95% BLOOD PRESSURE REPEATABILITY

1. Reference Device: Biopac Systems, ECG, 3-leads. Biopac respiration module with pneumatic belt, Biopac with continuous BP module, and Nurse using Auscultation Method, Framingham Study for risk prediction

Diahetes

Glucose HbA1c

Heart Disease

Cholesterol Triglycerides

Total HDL NT-pro-BNP Potassium

Kidney Disease

Serum Creatinine Hemoalobin

Validation 1

96.5% 100% HbA1c (SAMPLES) CHOLESTEROL (SAMPLES)

Compliance

1"Aina Blood Monitoring System" LBL AINA-13 C.pdf, Clinical studies include: National Health Group Diagnostics (SG), Fu Wai Hospitals (Beijing, CN), Narayana Health Hospitals (Bangalore, IN), Dr. Mohan's Diabetes Specialities Center (CHEN, IN), Study against the Siemens DCA Vantage (Bangalore, IN).

Assessment

Mobility Stability Strenath Movement Scores

Recovery Org. Validation 2



The University of Connecticu





1 AHI executed binding heads of agreement with

Physimax Technologies Limited in April 2021 and

2 Based on information included on the Physimax

is in the process of negotiating an acquisition

agreement and definitive terms. There is no

guarantee that this acquisition will occur.



Skin Conditions

Dermatitis Acne Carcinoma Eczema

Psoriasis Insect bites Shinales Warts

Scabies 588 Conditions

Accuracy, Validation 1

Compliance

CE

1. "Triage vs. USA Board-Certified Physicians". Company Overview September 2020

Global Verticals

Transforming User Engagement.



Life and Health Insurance.

Market size.

\$4.4T

Highlights.

- + Removes BMI-dependency.
- + Dynamic assessment.
- Limits the need to use expensive and inaccessible medical scanners and blood pressure monitors.
- Estimated premiums underwritten by AI support systems: \$20 billion by 2024, up from an estimated \$1.3 billion in 2019.

1. by 2020, "Global Life & Health Insurance Carriers Industry - Market Research Report", IBISWORLD, Aug 18 2020,

2. "Al-Underwritten Insurance Premiums to Go From \$1.3B to \$20B Globally by 2024" Juniper" Aug, 2019

mHealth.

Market size.

\$1.4T

Highlights.

- Telemedicine remote medical consultation.
- Virtual vital signs and chronic disease risk assessment.
- + Preventative care.
- Episodic Care Intervention.
- Company to make submission for CBD codes.

 in 2018, Sectors: TeleHealth, Workplace Wellness, Preventive & Personalized Medicine and Public Health, Healthy Eating, Nutrition & Weight Loss, "Move to be Well: The Global Economy of Physical Activity," PDF pg. X, Global Wellness Institute, 2019

A. in 2019, "Telehealth Market Size, Share & COVID-19 Impact Analysis, By Type...", Fortune Business Insights, Jul 2020

Fitness.

Market size.

\$1.1T

Highlights.

- + Track change.
- + Remote coaching results sharing.
- Digital appraisal.
- Body Composition tracking.

1. by 2023 "Physical Activity Is an \$828 Billion Market – To Reach \$1.1 Trillion+ by 2023" Global Wellness Institute, 2019.

Apparel.

Market size.

\$810B

Highlights.

- + 30-40% of online sales are returned.
- Auto-size and fit match algorithms.
- + Reduce time to purchase.
- + Custom Apparel.
- Increase retention and customer loyalty through better engagement and purchase personalization.

1. by 2023, "Apparet Global Market Report 2020-30: Covid 19 Impact and Recovery", Research & Markets, April 2020

.

B2B Business Model

Enabling operating cost efficiencies and the ability to leverage our partner's sales forces.

16 Active Partnerships

Targeting Over 7m Users From an Available Audience of Over 400m.



Product Integration 4 - 6 months depending on Partner Capability.


B2B, **multi-channel** approach with large digital environments.

Engaged Salesforce in key areas, including Asia, US, and UK.

Low-price, highvolume approach to sales in established environments. Enable our Partners to further monetize through knowledge and data previously unavailable remotely.

Raising US\$15M.

To grow and accelerate customers and revenue into 2022.



Key Customer Highlights.



Nexus-Vita, contracted revenue with initial target launch of application in January 2022.

- + AHI team currently building application set for December 2021 completion
- The platform empowers its users, clinicians, care teams, patients, and caregivers by having convenient, secure access to comprehensive health information (health records, claims, cost, and data from medical devices).
- + Contracted revenue of US\$4,100,000 for 2022.



App Launching Q1 2022 targeting 800.000 active users.

- FitTrack has a current revenue run rate for 2021 targeted at US\$89,000,000 with 800,000 active users.
- + FitTrack has undertaken to deliver a minimum of 500,000 paid users to the AHI technology in the first 12 months from launch.



Bearn App launching November/ December 2021 targeting 56,000,000 registered users.

- Bearn pays AHI US\$2.00 per BodyScan. The BodyScan is primary entry point of the Bearn App to be used by all users when earning rewards.
- + Bearn has undertaken to delivery a minimum of 1,000,000 paid users to AHI Technology in first 12 months from launch.



App launched October 2021 now aggressively marketing to 28,000,000 existing platform audience in China.

- + With a pre-existing 28,000,000 users on their platform.
- Tinjoy is now targeting 1,000,000 active paid monthly users in the first 12 months of launch.

Volume Based Pricing Model

Tier No	Tier Desc	Body Scans Cost Per Month, Per User *	Combined Body and Face Scans Per Month, Per User *
1	1 - 25,000 active users	USD\$4.99	USD\$6.99
2	25,001 - 50,000 active users	USD\$3.99	USD\$5.99
3	1 - 100,000 active users	USD\$2.99	USD\$4.99
4	100,001 - 250,000 active users	USD\$2.49	USD\$4.49
5	250,001 - 500,000 active users	USD\$1.99	USD\$3.99
6	500,001 - 1,000,000 active users	USD\$1.49	USD\$2.99
7	1,000,001 - 3,000,000 active users	USD\$1.00	USD\$1.99
8	> 3,000,000 active users	USD\$0.80	USD\$0.99

^{*} The above per month, per user pricing is tier based, where the Customer pays the per month, per user price for the first tier, then the per month, per user price for the second tier and so on.

- + NB 1: There is a minimum spend license fee of USD\$5,000 per month for the first 12 month as of the integrated solution go-live date.
- + NB 2: above revenues are either per month, per user tier based pricing or individual scan-based pricing to be paid to AHI or as mutually agreed under arrangement between the parties.
- + Monthly Face scan subscription is based on a monthly use policy, allowing the user to take up to 4 Face scans per month.
- + All above per month, per user pricing is based on a 12-month subscription or individual scans as outlined.

Growth Strategy.

Platform Expansion, More Partners = More Users.

Leveraging our Partners to Grow with an audience of over 400 million and an initial target of 7 million users.



Large Addressable Market

- + 4 global business verticals.
- Business partners are key to success.
- Audience reach with high volume paying customers.
- + Zero cost of marketing.



Investment in Innovation

- Building & licensing new software capabilities.
- Extending our platform to address a broader range of applications.
- Significant barrier to entry.

3.

Existing Customers and Growing.

- 16 binding agreements with an addressable audience of over 400 million.
- + Seamless integration.
- Pre and Post integration support.





MVMNT



Intellectual Property.

- Product suite secured through license and patents.
- No direct competitor identified with the broad suite of capabilities available through AHI.

Summary Income Statement.

(AUD)	For Years Ended June 30	
Income Statement	2020	2021
Revenues	\$667,197	\$1,202,337
Costs of Goods Sold	-	-
Gross Profit	667,197	1,202,337
Operating Expenses	6,729,927	16,047,741
Operating Income (Loss)	(6,062,730)	(14,845,404)
Income (Loss) before Tax	(\$6,062,681)	(\$14,845,404)
(+) Interest Expense	143,582	208,539
(+) Depreciation and Adjustment	245,645	349,387
EBITDA	(5,673,454)	(14,287,478)
(+) Stock based Compensation Adjustment	1,120,357	6,230,996
(+) Stock based Payments Adjustment	-	1,064,970
(+) Loss from Impairment of Assets	953,419	2,812,687
Adjusted EBITDA	(\$3,599,678)	(\$4,178,825)

Summary Balance Sheet.

(AUD)	As of June 30	
Balance Sheet	2020	2021
Total Cash	\$627,304	\$2,172,499
Accounts Receivable	294,122	243,300
Intangible Asset	1,373,492	1,215,915
Loan Receivable	-	682,421
Prepaid Expenses	294,568	905,355
Other Assets	365,021	201,709
Total Assets	\$2,954,507	\$5,421,199
Trade and Other Payables	785,939	555,057
Interest Bearing Borrowings (Current)	865,000	2,178,142
Other Current Liabilities	380,607	658,704
Lease Liabilities (Non-current)	138,124	51,212
Other Long Term Liabilities	322,331	-
Total Liabilities	\$2,492,001	\$3,443,115
Total Stockholders' Equity	462,506	1,978,084
Total Liabilities & Stockholders' Equity (Includes Non-Controlling Interests)	\$2,954,507	\$5,421,199

AHI Board of Directors.



Vlado Bosanac

Chairman & CEO

- Over 25 years experience in venture capital and private equity.
- + Entrepreneur, advisor and strategy consultant.
- Successfully funded 10+ start-ups, Extensive public company experience.
- + Highly experienced in transaction origination.



Mike Melby

Non-Executive Director

- + Fitness industry executive.
- Tech company founder (PayDivvy acquired by Higher One, TapIt - acquired by VC-backed Phunware).
- + Investment banker and private equity investor.
- + MBA Entrp. Man, BA, Political Economy.



Nick Prosser

Non-Executive Director

- + 15+ years experience in the ICT industry.
- Director of a number of private companies in Australia and Asia.
- + Former founder of Canberra Data Centres which were acquired by Infratil and Commonwealth Superannuation Corporation for an enterprise value of \$1.16 billion in 2016.



Dato Low Koon Poh

Non-Executive Director

- + Shareholder and Executive Director of an Singapore Exchange listed company.
- Over 20 years in accounting and corporate finance.
- + Entrepreneur, advisor and investor.
- + Fellow of ACCA (UK) and MIA (Malavsia).



Edward Greissing

Non-Executive Director

- Senior executive leader, and public health expert with over 40 years of management experience, commercial focus, and talent development.
- Member of the Executive Committee, Global Leadership Team, and Senior VP of Corporate Affairs at Sanofi.
- Former Executive Director, Milken Institute, former President and CEO, Red Line Associates, former VP Global Government Affairs and Policy.

Management Team.



Steven Richards

CFO, Company Secretary

- + Qualified Chartered Accountant 15+ years experience at CFO level.
- Worked in high-growth and tech environments at PUMA Sports, Quicksilver, HealthEngine, Airscope industries, and RameSys Global.
- (Hons) B.Comm, MBA, Chartered Accountant, Finance, Leadership and Strategy.



Bill Bradford

Chief Business Officer, USA

- Currently Chief Product Officer at Pvolve FitTech startup based in NYC.
- Recently Chief Digital Officer at Beachbody, LLC launched Beachbody on Demand leading to US\$1 Billion in total annual revenue.
- Former U.S. Army Officer, Previously SVP, Digital Media Fox Broadcasting (Fox.com), VP, Product Management – Yahoo!, AOL Executive Director, Product Management.



Dr Amar Fl-Sallam

Chief Science Officer

- Over 25 years of expertise in the R&D space in many areas, including signal, speech and image processing, CV, ML, human shapes, human movements, human medical images, sports, health, and clinical science.
- + Former Research Scientist WA/AU Institute of Sport
- Former Senior Research Fellow School of CS and SE, UWA, former Research Fellow School of Sport Science, Exercise and Health, UWA.



Terence Stupple

Chief Technology Officer

- + Former Web Specialist Chevron Australia.
- Former Manager, Web Services Department of Mines and Petroleum, Department of State Development - West Australian Government Agencies
- Former Licensing Specialist Microsoft (UK) Global Software Company



Investment Highlights.

- + Robust commercial network: Current agreements include 16 active Partnerships targeting over 7m users from an available audience of over 400m.
- + Large addressable market with many verticals.
- + Cutting Edge Innovative and proprietary technology in a Global and fast-growing industry.
- + B2B business model enabling rapid growth and scalability through existing and growing networks.
- + Experienced management team with a successful track record.




















Appendix.

Unlocking Personalized Assessment Through Data Convergence.

Unlock significant aspects of an individual's health, fitness and wellbeing via the convergence of on-device scanning and external data.



Mobile Device Health Information System Empowering Early Intervention With Actionable Data.

Computer Vision and Image Processing technology are already widely used in the healthcare industry. Still, many healthcare services are performed using traditional methods.

> Innovation in Computer Vision and Image Processing will reveal potentially disruptive applications.



Identifying risk and the evolution of chronic disease.



Using AI and image analysis for more accurate and convenient diagnosis.



Reducing the burden on the global healthcare system.



Injury prevention and rehabilitation through human movement analysis.



Enhancing and improving on human error.

Potential Acquisition



Issued Patents




















COMPLETESCAN

BodyScan.

Anatomy and Biomechanics, The University of Western Australia - ASX Announcement 18/10/2018.

3D Artwork by Aleksandrs K

A pioneering body scan technology by AHI. It combines proprietary deep learning models and state of the art image processing techniques that return body circumference, body composition, multiple health risks, and indicators.



FaceScan.

Transdermal Optical Imaging techniques pave the way to a non-intrusive and easy-to-use method for measuring vital signs, and risks associated with Chronic Disease.

+ Fitness

+ mHealth

+ Life & Health Insurance

Vital Signs, Unlocked

- + Advanced facial tracking locks onto key regions of interest
- + Transdermal Optical Imaging (TOI) is used to extract facial blood flow information from beneath the skin
- Advanced signal processing and deep learning models measure vital signs and predict physiological and psychological effects

Accuracy & Validation

99% HEART RATE	95% BLOOD PRESSURE SYSTOLIC	95% BLOOD PRESSURE DIASTOLIC
95% PULSE PRESSURE	99% REPEATABILITY	

Platforms












² Metabolic Syndrome is available by combining a Face Scan and BodyScan data, or supplying Blood Pressure.

3D Artwork by Hossam Ahmed



DermaScan.

The intelligent, instant dermatological scanner with superhuman diagnostic capabilities, capable of screening for over 500 skin conditions.

+ mHealth

+ Life & Health Insurance

Instant. Accurate. Affordable.

- + Self-training AI that improves with every scan.
- + DermaScan can detect 588 skin conditions in 133 categories, from the common to the complex.
- Save time and increase patient throughput.
- Instant second opinion leads to better outcomes.
- Reduce malpractice risk.
- Attach a dermatoscope for enhanced accuracy.
- + Over 160,000 users. Used over 500,000 times, with 12% of the user base being clinicians.

Clinical Validation

87% ACCURACY

54%

73%

Standards

95%

Platforms






CE



Questions



^{1.&}quot;Triage vs. USA Board-Certified Physicians". Company Overview September 2020.

MKScan.

Empowering athletes to independently perform functional movement assessments; Instantly obtaining objective feedback with: Mobility, Stability, Strength, and Movement Control scores.

+ Fitness

+ mHealth

+ Life & Health Insurance

Highlights

- Time Saving Instant set-up, 8minute pro assessment and real-time feedback. Save precious time for staff and athletes alike.
- Objective Measurements -Automated screening process ensures consistent scores, eliminating the need for any expertise or prior knowledge.
- + Comprehensive Coverage -Offers the widest range of automated evidence-based functional movement tests.

- Comparative Scores Athlete scores are calculated in relation to same level norms, maximizing the accuracy level of the results.
- Portability Perform automated movement assessments anytime, anywhere.
- Large-Scale Assessments proven to assess hundreds of subjects in just a few hours, the ultimate solution for colleges, youth academies and tactical forces.







Validation

Validated by world-leading academic institutions.



The University of North Carolina



The University of Connecticut



Military Academy at West Point

HemaScan.

The low-cost and accessible point of care blood diagnostics and monitoring solution.

+ Fitness

+ mHealth

+ Life & Health Insurance

Highlights

- The patented Aina device provides rapid, accurate readouts of key blood chemistry elements in several chronic disease categories: Cardiovascular, Renal, and Metabolic (CVRM).
- + Low-cost, point-of-care (POC) blood diagnostics that is accessible and affordable.
- + Real-time, lab-quality results within minutes.
- + Simple to Use.
- + Seamless Connectivity.

Aina Device

The Aina tests include:

- + Diabetes HbA1c and glucose.
- Heart disease: Total cholesterol, triglycerides, total HDL cholesterol, NT-pro-BNP, and Potassium.
- Kidney disease: Serum
 Creatinine and hemoglobin.

Clinical Validation

HbA1c	Glucose	Hemoglobin
97.6% samples within 10% bias	96.5% samples within 15% bias	94.4% samples within 10% bias
Total Cholesterol	HDL Cholesterol	Triglycerides
100% samples within 15% bias	100% samples within 15 mg/dL bias	97.6% samples within 15% bias

Compliance













The Path To Go-Live.

technology and determine how we can work

Terms of partnership agreed upon and signed.

together.

Whilst the destination is important, having a smooth path to get there is paramount. Here's what to expect.

integration points for the scans and lock in

user flows and app designs.



MultiScan SDK into your app based on the agreed Solution Design. Utilize our reference code and

developer documentation to empower your

technical team.

Go-Live

Go-Live subject to partner's discretion.

We continue to support you. Your success is our success.

everything is in

working order.

Integration Example: Fitness.

In App and On-device Fitness Results Tracking.

† BODYSCAN

FACE SCAN





A new member signs up for a fitness app. As part of the onboarding, the member sets fitness goals and takes a body and face scan. A recommended program is displayed based on their goals and scan results.



eCoach Interaction.

An in-app guide ensures a recent face and body scan is completed before the coach can prepare the program for the member's unique health profile.



eCoach Interaction.

The coach can view the changes so far during the program, making corrections where necessary.



Real-time Workout Monitoring.

During workout stages, the pulse is measured using the face scan. Both the coach and member can see the results, ensuring the target activity level is maintained.



Program Summary.

Once the program is completed, the summary screen shows where the most change occurred on the 3D model.



VERTICAL

Integration Example: Life/Health Insurance.


Dynamic Underwriting, Chronic Disease Intervention, and Prevention.





EXAMPLE 1











Health Assessment

Face and BodyScan technology is available to policyholders, allowing athome assessment of chronic diseases. Results to Action

The results are sent to the provider and shown to the policyholder, showing them what course of action to take next.

The provider intervenes and provides extra support to improve health and reduce risk.

(C)

Road to Prevention

A regular Face and BodyScan are conducted while on a health journey, showing improvement trends and validating providers' offerings. Self-Reported Application

A recent Face and BodyScan is submitted by a potential policyholder, along with self-reported information, such as height and weight.

Self-reported weight shows nominal health.

Weight inference is used to calculate alternate results, along with Health Risks.

Integration Example: Apparel.

Auto-Sizing and Auto-Fit.


† BODYSCAN

EXAMPLE 1











are the correct size.

QR Codes
Size and fit options are auto-matched by brand, driving online and in-store shopping experiences.

EXAMPLE 2







Custom art, initials, and branding graphics can be placed by an individual shopper, creating truly custom clothing.



Final custom apparel purchase with all personalization intact, ready for express checkout.



Integration Example: mHealth.

Remote Assessment and Health Monitoring.





EXAMPLE 1













Booking Appointment

Remote appointment booked with a remote medical professional.



Sharing Results

Once scans are complete, the results are shared with the medical professional.



Video Appointment

During the call, the scan results are displayed and discussed by the medical professional.



Professional Advice

Feedback from the health professional contains lifestyle, diet and nutrition, exercise, and sleep adjustments in order to improve health conditions.





Built-in Monitoring

Doctor-patient monitoring allows for progress to be tracked remotely.

Patients provide extended feedback with each weekly scan assessment.

Accessible Healthcare through early intervention with actionable data.



Trip to Doctor, Specialist



Doctors, Nurses



Pathology



ECG Machine



Blood Pressure Monitor



Respiration Belt Sensor



ISAK Accredited Professional



Tape measure. calipers



DEXA Scanner



Body composition scanner, scales



Dermatologist



Musculoskeletal Physician



BodyScan



FaceScan



DermaScan

MKScan



HemaScan





ASX: AHI

www.advancedhumanimaging.com

Vlado Bosanac

CEO, Co-Founder

vlado.bosanac@advancedhumanimaging.com

Bill Bradford

Chief Business Officer, USA bill.bradford@advancedhumanimaging.com

Nadine Amesz

Operations Officer nadine.amesz@advancedhumanimaging.com